1-YEAR SUSTAINABILITY OF THE MINIMED™ 670G SYSTEM OUTCOMES IN REAL-WORLD CONDITIONS

被引：0
|
作者：
Da Silva, J. [1 ]
Arrieta, A. [2 ]
Castaneda, J. [2 ]
Cohen, O. [1 ]
机构：
[1] Medtron Int Trading Sarl, Med Affairs, Tolochenaz, Switzerland
[2] Medtronic, Bakken Res Ctr, Maastricht, Netherlands
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P006 / #18
引用
收藏
页码：A74 / A74
页数：1
相关论文
共 50 条
  • [41] Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review
    Mameli, Chiara
    Smylie, Giulia Marie
    Galati, Alessio
    Rapone, Biagio
    Cardona-Hernandez, Roque
    Zuccotti, Gianvincenzo
    Delvecchio, Maurizio
    EUROPEAN JOURNAL OF PEDIATRICS, 2023, 182 (05) : 1949 - 1963
  • [42] The Effectiveness of Virtual Training on the MiniMed 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic
    Vigersky, Robert A.
    Velado, Kevin
    Zhong, Alex
    Agrawal, Pratik
    Cordero, Toni L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (02) : 104 - 109
  • [43] Overnight to Early-Morning Glycemic Outcomes in Children Using the MiniMed™ 670G Hybrid Closed-Loop (HCL) System
    Forlenza, Gregory P.
    Shulman, Dorothy I.
    Wood, Michael A.
    Bailey, Timothy S.
    Bode, Bruce W.
    Buckingham, Bruce
    Huang, Suiying
    Shin, John
    Lee, Scott W.
    Cordero, Toni L.
    Kaufman, Francine R.
    DIABETES, 2018, 67
  • [44] The MiniMed™ 670G Hybrid Closed-Loop (HCL) System and Patient-Reported Outcomes Concerning Quality of Life Measures
    Gopalakrishnan, Shweta
    Fogel, Catherine
    Mueckler, John
    DIABETES, 2018, 67
  • [45] Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
    Da Silva, Julien
    Lepore, Giuseppe
    Battelino, Tadej
    Arrieta, Arcelia
    Castaneda, Javier
    Grossman, Benyamin
    Shin, John
    Cohen, Ohad
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (02) : 113 - 119
  • [46] TIME IN TARGET GLUCOSE RANGE AND GLYCATED HEMOGLOBIN LEVELS DURING THE MINIMED 670G SYSTEM PIVOTAL TRIALS
    Shin, J.
    Liu, M.
    Chen, X.
    Cordero, T.
    Lee, S.
    Kaufman, F.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A85 - A86
  • [47] COST EFFECITVENESS ANALYSIS OF MINIMED 670G SYSTEM VERSUS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION, IN INDIVIDUALS WITH TYPE 1 DIABETES
    Jendle, J.
    de Portu, S.
    Roze, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A78 - A79
  • [48] Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
    Messer, Laurel H.
    Forlenza, Gregory P.
    Sherr, Jennifer L.
    Wadwa, R. Paul
    Buckingham, Bruce A.
    Weinzimer, Stuart A.
    Maahs, David M.
    Slover, Robert H.
    DIABETES CARE, 2018, 41 (04) : 789 - 796
  • [49] The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed 670G Hybrid Closed-Loop System
    Cordero, Toni L.
    Garg, Satish K.
    Brazg, Ronald
    Bailey, Timothy S.
    Shin, John
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (12) : 749 - 752
  • [50] Glycemic control outcomes of adults using the MiniMed™ 670G hybrid closed-loop (HCL) system: A single-center study
    Al Qifari, S. F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 158
12345